Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children - CIRI - Activation et transduction du signal dans les lymphocytes
Article Dans Une Revue RMD Open : Rheumatic & Musculoskeletal Diseases Année : 2016

Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children

Résumé

Arthritis is one of the main manifestations of mixed connective tissue disease (MCTD) and overlap syndrome in children and can be responsible for functional disability. We report on 2 children with arthritis that were dramatically improved by a treatment with interleukin-6 (IL-6) blockers in the context of connective tissue disease. However, in both cases, other systemic autoimmune symptoms were not modified by the treatment and autoantibodies tend to increase, suggesting a differential effect of IL-6 inhibition on articular inflammation and systemic autoimmunity.
Fichier principal
Vignette du fichier
e000271.full.pdf (2 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-01911117 , version 1 (20-02-2024)

Identifiants

Citer

Natalia Cabrera, Agnes Duquesne, Marine Desjonquères, Jean-Paul Larbre, Jean-Christophe Lega, et al.. Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children. RMD Open : Rheumatic & Musculoskeletal Diseases, 2016, 2 (2), pp.e000271. ⟨10.1136/rmdopen-2016-000271⟩. ⟨hal-01911117⟩
112 Consultations
38 Téléchargements

Altmetric

Partager

More